These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 11083268)

  • 21. Regulatory B Cells in Systemic Sclerosis Isolated or Concomitant With Hashimoto Thyroiditis.
    Capriello S; Ferrari SM; Gatto I; Santaguida MG; Fallahi P; Antonelli A; Mangino G; Romeo G; Virili C; Centanni M
    Front Immunol; 2022; 13():921260. PubMed ID: 35874691
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 1,25OH-Vitamin D3 and IL-17 Inhibition Modulate Pro-Fibrotic Cytokines Production in Peripheral Blood Mononuclear Cells of Patients with Systemic Sclerosis.
    Corrado A; Rotondo C; Sanpaolo ER; Altomare A; Maruotti N; Cici D; Cantatore FP
    Int J Med Sci; 2022; 19(5):867-877. PubMed ID: 35693738
    [No Abstract]   [Full Text] [Related]  

  • 23. The Pathophysiological Roles of Regulatory T Cells in the Early Phase of Systemic Sclerosis.
    Kobayashi S; Nagafuchi Y; Shoda H; Fujio K
    Front Immunol; 2022; 13():900638. PubMed ID: 35686127
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Mechanistic Insight into the Pathogenic Role of Interleukin 17A in Systemic Autoimmune Diseases.
    Bisoendial R; Lubberts E
    Mediators Inflamm; 2022; 2022():6600264. PubMed ID: 35620115
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Skin Manifestation Induced by Immune Checkpoint Inhibitors.
    Yamamoto T
    Clin Cosmet Investig Dermatol; 2022; 15():829-841. PubMed ID: 35592732
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of interleukin-17 in the pathogenesis of systemic sclerosis: Pro-fibrotic or anti-fibrotic?
    Bellando-Randone S; Della-Torre E; Balanescu A
    J Scleroderma Relat Disord; 2021 Oct; 6(3):227-235. PubMed ID: 35387209
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Possible role of adipocytokines in systemic sclerosis-associated small pericardial effusion.
    Chialà A; Rotondo C; Praino E; Natuzzi D; Cacciapaglia F; Iannone F
    J Scleroderma Relat Disord; 2018 Jun; 3(2):153-158. PubMed ID: 35382240
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Contributions of Immune Cells and Stromal Cells to the Pathogenesis of Systemic Sclerosis: Recent Insights.
    Dai B; Ding L; Zhao L; Zhu H; Luo H
    Front Pharmacol; 2022; 13():826839. PubMed ID: 35185577
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Systemic Sclerosis: From Pathophysiology to Novel Therapeutic Approaches.
    Benfaremo D; Svegliati S; Paolini C; Agarbati S; Moroncini G
    Biomedicines; 2022 Jan; 10(1):. PubMed ID: 35052842
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Body mass index and adipokines/cytokines dysregulation in systemic sclerosis.
    Iannone F; Praino E; Rotondo C; Natuzzi D; Bizzoca R; Lacarpia N; Fornaro M; Cacciapaglia F
    Clin Exp Immunol; 2021 Nov; 206(2):153-160. PubMed ID: 34358345
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The interplay of DAMPs, TLR4, and proinflammatory cytokines in pulmonary fibrosis.
    Bolourani S; Brenner M; Wang P
    J Mol Med (Berl); 2021 Oct; 99(10):1373-1384. PubMed ID: 34258628
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Role of T Lymphocytes in Cutaneous Scarring.
    Short WD; Wang X; Keswani SG
    Adv Wound Care (New Rochelle); 2022 Mar; 11(3):121-131. PubMed ID: 34238032
    [No Abstract]   [Full Text] [Related]  

  • 33. Cytokines Involved in the Pathogenesis of SSc and Problems in the Development of Anti-Cytokine Therapy.
    Shima Y
    Cells; 2021 May; 10(5):. PubMed ID: 34064515
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Engineering Advanced In Vitro Models of Systemic Sclerosis for Drug Discovery and Development.
    De Pieri A; Korman BD; Jüngel A; Wuertz-Kozak K
    Adv Biol (Weinh); 2021 Apr; 5(4):e2000168. PubMed ID: 33852183
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Blocking IL-17: A Promising Strategy in the Treatment of Systemic Rheumatic Diseases.
    Rafael-Vidal C; Pérez N; Altabás I; Garcia S; Pego-Reigosa JM
    Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 32993066
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Involvement of nuclear factor erythroid 2‑related factor 2 in neonatal intestinal interleukin‑17D expression in hyperoxia.
    Liu X; Zhang D; Cai Q; Liu D; Sun S
    Int J Mol Med; 2020 Oct; 46(4):1423-1432. PubMed ID: 32945417
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Systemic Sclerosis Perturbs the Architecture of the Immunome.
    Paleja B; Low AHL; Kumar P; Saidin S; Lajam A; Nur Hazirah S; Chua C; Li Yun L; Albani S
    Front Immunol; 2020; 11():1602. PubMed ID: 32849542
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Psoriasis and Connective Tissue Diseases.
    Yamamoto T
    Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32823524
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Urinary biomarkers in lupus nephritis.
    Aragón CC; Tafúr RA; Suárez-Avellaneda A; Martínez MT; Salas AL; Tobón GJ
    J Transl Autoimmun; 2020; 3():100042. PubMed ID: 32743523
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Role of Endogenous Eicosapentaenoic Acid and Docosahexaenoic Acid-Derived Resolvins in Systemic Sclerosis.
    Avanoǧlu Güler A; Rossi FW; Bellando-Randone S; Prevete N; Tufan A; Manetti M; de Paulis A; Matucci-Cerinic M
    Front Immunol; 2020; 11():1249. PubMed ID: 32636845
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.